Rocket Lab SEC Filings

Revenue reached $436M (+78% YoY) driven by 16 Electron launches and space systems growth. Operating losses widened to $190M amid Neutron development and scaling. Backlog strengthened to $1.06B with $450M new contracts signed.

This DEF 14A is Rocket Lab's proxy for its August 27, 2025 virtual annual meeting. Key proposals: elect three Class I directors (Olson, Saintil, Slusky); ratify Deloitte as 2025 auditors; advisory approval of exec comp; amend subsidiary charter to remove pass-through voting post-holding co reorg. Investors should note CEO Beck's large RSU grants and preferred stock exchange with his trust.

DEFA14A additional materials for RKLB 2025 Annual Meeting on Aug 27. Key proposals: elect Class I directors Jon Olson, Merline Saintil, Alex Slusky; ratify Deloitte auditors; advisory approval of NEO compensation; amend subsidiary certificate to remove pass-through voting. Board recommends FOR all.

Khosla Ventures V, L.P., a 10% owner controlled by Director Vinod Khosla, disposed of 2,000,000 common shares via pro rata distribution to partners for no consideration. It now beneficially owns 19,323,617 shares indirectly. Neutral signal as no market transaction occurred.

This is a preliminary proxy statement for the August 27, 2025 annual meeting following a May 2025 holding company reorganization. Key proposals include electing three Class I directors, ratifying Deloitte as auditor, advisory approval of executive compensation, and amending Rocket Lab USA, Inc.'s charter to eliminate the pass-through voting provision. The filing is relevant to investors as it discloses governance changes and standard annual meeting matters post-reorganization.

Merline Saintil, a Director at Rocket Lab USA Inc., sold 6,353 shares of common stock on June 24, 2025, at weighted average prices of $33.1473 and $33.7848. The transactions were automatic pursuant to a Rule 10b5-1 trading plan adopted on March 20, 2025. This represents a neutral signal as it is a pre-scheduled, non-discretionary sale.

Merline Saintil, Director at Rocket Lab USA, sold 6,353 common shares on 06/20/2025 at weighted average prices of $28.75 and $29.65, leaving 425,922 shares directly owned. The transaction was automatic under a Rule 10b5-1 plan adopted on 03/20/2025. Neutral signal due to pre-scheduled nature.

Rocket Lab director Merline Saintil filed Form 144 to sell 12,706 common shares acquired via RSU vesting on June 12, 2025, with aggregate value of $353,862. The sale, set for approx. June 20, 2025, follows a Rule 10b5-1 plan adopted March 20, 2025; no prior sales in past 3 months. This routine insider transaction is minor relative to 461M shares outstanding.

Matthew Ocko, a director of Rocket Lab USA, indirectly sold approximately 1,020,000 shares through managed funds DCVC IV and DCVC Opportunity Fund II on June 12-13, 2025. Total value around $26.6M at weighted average prices of $26.44 and $26.01. This large discretionary sale signals moderate bearish insider sentiment.

This Schedule 13D/A amendment discloses that CEO Peter Beck's Equatorial Trust entered a Rule 10b5-1 plan on June 13, 2025, to sell up to 5M common shares via Goldman Sachs, starting September 15 and ending December 17, 2025. The Trust converted 5M preferred shares to common on June 17 for the plan; Beck beneficially owns 51.3M shares (10.02%). Relevant for investors as it signals structured insider selling for diversification and philanthropy.